Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor

Study Overview
=================
Brief Summary
-----------------
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with malignant tumor. [18F]Fluoroglutamine PET may provide additional information that help diagnose and stage cancer patients.

Official Title
-----------------
18F-(2S,4R)4-Glutamine PET/CT in Imaging Patients With Malignant Tumor

Conditions
-----------------
Cancer, Metastatic Cancer, Metastatic Brain Cancer

Intervention / Treatment
-----------------
* Radiation: 18F-(2S,4R)4-fluoroglutamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-79; The patient must be able to give informed consent; Patients can finish PET/CT scan without tranquilizers; Patients with pathology-proven cancer or a tumor highly suspected to be malignant ; Lesions can be measured and assessed at the RECIST 1.1 standard; No chemotherapy, radiotherapy or immune/biologic therapy,or biopsy were allowed between the 18F-FDG and the 4-[18F]Fluoroglutamine PET/CT. Exclusion Criteria: Pregnant or lactating patients; Inability or refusal to have at least one peripheral intravenous line for intravenous access; From assays obtained <2 weeks prior to study enrollment（ULN：the upper limit of normal value ）:Bilirubin>1.5*ULN,AST/ALT >2.5 * ULN, Albumin< 3 g/dl, GGT > 2.5 x ULN if ALP> 2.5 x ULN, Creatinine>1.5*ULN or creatinine clearance <60ml/min； Patients with a history of allergic reaction to this drugs or its analogues； patients with poor compliance; Acute major illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 4-[18F]Fluoroglutamine<br>Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy. | Radiation: 18F-(2S,4R)4-fluoroglutamine<br>* Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosing and Staging ability of 4-[18F]Fluoroglutamine PET/CT in malignant cancer | Sensitivity, specificity, diagnostic accuracy of 4-[18F]Fluoroglutamine and 18F-FDG PET/CT will be compared using paired t-test or Krusal-Wallis test. | up to three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Treatment-Emergent Adverse Events | The evaluation of the Incidence of Treatment-Emergent Adverse Events starts from the day of F-Gln examination until 30 days later; Treatment-Emergent Adverse Events are evaluated according to version 4.03 CTC-AE criteria. | up to 30 days after the F-Gln imaging | 
| ASCT2 expression levels in tissue samples | Wilcoxon rank-sum or Kruskal-Wallis tests will be applied for the group comparisons of IHC staining(ASCT2) | up to three years | 
| The correlation between 18F-(2S,4R)4- glutamine PET/CT imaging and prognosis in malignant tumors | Evaluating the prognostic value of metabolic parameters and clinical indexes by using log-rank tests on univariate analysis and COX proportional hazards regression tests | up to three years |